Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Gains from Investment Securities (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Gains from Investment Securities data on record, last reported at $1.2 million in Q2 2025.

  • For Q2 2025, Gains from Investment Securities rose 69.23% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $274000.0, down 88.31%, while the annual FY2025 figure was $29000.0, 98.76% down from the prior year.
  • Gains from Investment Securities reached $1.2 million in Q2 2025 per OCUL's latest filing, up from $1.0 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $6.8 million in Q4 2021 and bottomed at $1000.0 in Q3 2022.
  • Average Gains from Investment Securities over 5 years is $1.5 million, with a median of $1.0 million recorded in 2025.
  • Peak YoY movement for Gains from Investment Securities: plummeted 99.96% in 2023, then soared 152601.9% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at $6.8 million in 2021, then plummeted by 99.99% to $1000.0 in 2022, then skyrocketed by 27300.0% to $274000.0 in 2023, then soared by 755.3% to $2.3 million in 2024, then tumbled by 47.17% to $1.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $1.2 million in Q2 2025, $1.0 million in Q1 2025, and $2.3 million in Q4 2024.